Biologic agents in COPD management

Rev Mal Respir. 2023 Dec 20:S0761-8425(23)00291-7. doi: 10.1016/j.rmr.2023.11.003. Online ahead of print.ABSTRACTChronic obstructive pulmonary disease (COPD) is a frequently occurring disease entailing high morbidity and mortality, and relevant therapeutic resources are limited. As is the case with asthma, the current trend consists in the phenotyping of COPD patients so as to develop personalized medicine tailored to a given individual's inflammatory profile. The aim of this review is to summarize the role of biologic agents in the management of COPD, taking into consideration not only COPD pathophysiology, but also the previously published studies and the relatively encouraging prospects for the future.PMID:38129268 | DOI:10.1016/j.rmr.2023.11.003
Source: Revue des Maladies Respiratoires - Category: Respiratory Medicine Authors: Source Type: research